Basics Brainstorm Cell Therapeutics Inc. Brainstorm Cell Therapeutics Inc is a biotechnology company. The Company develops novel adult stem cell therapies for debilitating neurodegenerative disorders such as ALS, MS, and PD among others. IPO Date: November 1, 2003 Sector: Healthcare Industry: Biotech Activated in VL: True Average Daily Range Avg Daily Range: $0.11 | 3.46% Avg Daily Range (30 D): $0.02 | 3.44% Avg Daily Range (90 D): $0.03 | 3.91% Institutional Daily Volume Avg Daily Volume: .35M Avg Daily Volume (30 D): .02M Avg Daily Volume (90 D): .14M Trade Size Avg Trade Size (Sh.): 256 Avg Trade Size (Sh.) (30 D): 638 Avg Trade Size (Sh.) (90 D): 375 Institutional Trades Total Inst.Trades: 43 Avg Inst. Trade: $2.23M Avg Inst. Trade (30 D): $.62M Avg Inst. Trade (90 D): $.62M Avg Inst. Trade Volume: .03M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $3.72M Avg Closing Trade (30 D): $M Avg Closing Trade (90 D): $M Avg Closing Volume: 29.88K     News Aug 14, 2025 @ 11:02 AM BrainStorm Cell Therapeutics Announces Second Quar... Source: Prnewswire Jul 18, 2025 @ 9:36 AM Brainstorm Cell Therapeutics Crashes 42% After Vol... Source: Mohd Haider May 6, 2025 @ 11:00 AM BrainStorm to Present Biomarker Insights Supportin... Source: Prnewswire Mar 26, 2025 @ 12:15 PM BrainStorm Cell Therapeutics Granted Compliance Ex... Source: Prnewswire Feb 21, 2025 @ 6:00 PM Cell and Gene Therapies in Rare Disorders Market t... Source: Delveinsight Financials   TTM Q2 2025 Q1 2025 Basic EPS $-1.79 $-.34 $-.45 Diluted EPS $-1.79 $-.34 $-.45 Revenue $ $ $ Gross Profit $ $ $ Net Income / Loss $ -11.45M $ -2.9M $ -2.86M Operating Income / Loss $ -11.9M $ -2.57M $ -3.09M Cost of Revenue $ $ $ Net Cash Flow $ -4.41M $ M $ M PE Ratio     Splits Oct 01, 2024:   1:15 Sep 16, 2014:   1:15 Aug 13, 2003:   2:1